Your Best Stock
Stocks MET

MetLife MET

US equityMarket cap rank #261
$97.65
+$0.45 (+0.46%)
Market open · Sep 24, 1:10 pm ET
After hours $96.40 -0.83%
Open$97.33
Prev close$97.20
Day range$97.06 – $98.18
Volume1.26M
Market cap$62.05B
P/E (TTM)18.7
Dividend yield2.35%
  • Hailanxin (300065.SZ): No overseas orders for underwater data centers have met disclosure standards. Gelonghui Finance · 8 Sep 2026
  • Top U.S. Stock Performers This Week | Roivant Sciences surged more than 17% this week as Phase II data for mosliciguat, developed by its subsidiary, met endpoints in treating PH-ILD; Cloudflare rose nearly 12%, indirectly benefiting as an edge computing p Market news · 11 Sep 2026
  • US August PPI month-on-month growth met expectations, while year-on-year growth slightly exceeded forecasts. Global Market Briefing · 10 Sep 2026
  • Court Closes Light S.A. Judicial Reorganization After Plan Obligations Met TipRanks · 10 Sep 2026
  • The new iPhone launch met expectations and drove an increase in ASP, but the outlook for the iPhone remains uncertain. CSOP · 10 Sep 2026
  • Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily discloses an announcement regarding the interim analysis of its Phase III clinical trial of Yizekang® (LunKang Yilong Tuodan Kang, BL‑B01D1/iza‑bren) for the treatment of locally advanced, recurrent, or metastatic HR+HER2‑negative breast cancer, which has met the primary endpoint. SZSI · 26 Aug 2026
  • Guangting Information: Verification Opinion of the Board\'s Remuneration and Assessment Committee on Whether the Vesting Conditions for the First Vesting Period of the Initial Grant under the 2025 Restricted Stock Incentive Plan Have Been Met. SZSI · 9 Jun 2026
  • 4: Warrior Met Coal | 4: Statement of changes in beneficial ownership of securities-Officer Gant Kelli K. SEC · 5 Jun 2026
  • JUNSHI BIO: Overseas Regulatory Announcement – Junshi Biosciences Co., Ltd. Voluntarily Discloses that the Phase III Clinical Trial of Toripalimab in Combination with Chemotherapy for Perioperative Treatment of Patients with Resectable Stage II–III Non-Small Cell Lung Cancer Has Met Its Primary Endpoint at Final Analysis HKEX · 26 May 2026
  • Laimu Co., Ltd.: Announcement by Laimu Co., Ltd. on the Completion of Cancellation of Stock Options for the Third Exercise Period of the 2023 Stock Option Incentive Plan, as the Exercise Conditions Were Not Met SZSI · 14 May 2026
Scroll to Top